Nrx pharmaceuticals (nasdaq: nrxp) announces last patient, last visit in its phase 2b/3 trial of nrx-101 in suicidal treatment resistant bipolar depression

Marks a major step in the development of what could be the first drug approved for suicidal bipolar depression the study database is being cleaned and locked; statistical analysis and top-line data to follow shortly thereafter study maintained 95% concordance rate between study sites and central raters on primary endpoint. no unexpected serious adverse events were reported.
NRXP Ratings Summary
NRXP Quant Ranking